Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2000 1
2004 1
2006 1
2007 1
2008 7
2009 6
2010 5
2011 4
2012 9
2013 19
2014 13
2015 21
2016 28
2017 20
2018 29
2019 36
2020 27
2021 28
2022 10
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 31092443

236 results

Results by year

Filters applied: . Clear all
Page 1
An Exploratory Randomized Phase II Trial Comparing CDDP Plus S-1 With Bevacizumab and CDDP Plus Pemetrexed With Bevacizumab Against Patients With Advanced Non-squamous Non-small Cell Lung Cancer.
Kaira K, Imai H, Souma R, Sakurai R, Miura Y, Sunaga N, Kasahara N, Tsukagoshi Y, Koga Y, Kitahara S, Kotake M, Minato K, Naruse I, Fukushima Y, Hisada T, Ishizuka T. Kaira K, et al. Anticancer Res. 2019 May;39(5):2483-2491. doi: 10.21873/anticanres.13368. Anticancer Res. 2019. PMID: 31092443 Clinical Trial.
Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression.
Cardona AF, Rojas L, Wills B, Arrieta O, Carranza H, Vargas C, Otero J, Cuello M, Corrales L, Martín C, Ortiz C, Franco S, Rosell R; CLICaP. Cardona AF, et al. PLoS One. 2016 May 18;11(5):e0154293. doi: 10.1371/journal.pone.0154293. eCollection 2016. PLoS One. 2016. PMID: 27191954 Free PMC article.
Phase II study of cisplatin/pemetrexed combined with bevacizumab followed by pemetrexed/bevacizumab maintenance therapy in patients with EGFR-wild advanced non-squamous non-small cell lung cancer.
Fukushima T, Wakatsuki Y, Kobayashi T, Sonehara K, Tateishi K, Yamamoto M, Masubuchi T, Yoshiike F, Hirai K, Hachiya T, Koizumi T. Fukushima T, et al. Cancer Chemother Pharmacol. 2018 Jun;81(6):1043-1050. doi: 10.1007/s00280-018-3573-0. Epub 2018 Apr 11. Cancer Chemother Pharmacol. 2018. PMID: 29644460 Clinical Trial.
Phase II trial of induction chemotherapy of pemetrexed plus split-dose cisplatin followed by pemetrexed maintenance for untreated non-squamous non-small-cell lung cancer.
Koba T, Minami S, Nishijima-Futami Y, Masuhiro K, Kimura H, Futami S, Yaga M, Mori M, Kagawa H, Uenami T, Kohmo S, Otsuka T, Yamamoto S, Komuta K, Kijima T. Koba T, et al. Cancer Chemother Pharmacol. 2018 Jul;82(1):111-117. doi: 10.1007/s00280-018-3598-4. Epub 2018 May 4. Cancer Chemother Pharmacol. 2018. PMID: 29728800 Clinical Trial.
Switch maintenance therapy with docetaxel and bevacizumab after induction therapy with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous non-small cell lung cancer: a phase II study.
Nishimoto K, Karayama M, Inui N, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Inami N, Matsuura S, Kaida Y, Matsui T, Asada K, Matsuda H, Fujii M, Toyoshima M, Imokawa S, Suda T. Nishimoto K, et al. Med Oncol. 2018 Jun 16;35(7):108. doi: 10.1007/s12032-018-1172-x. Med Oncol. 2018. PMID: 29909581 Clinical Trial.
Randomized phase II study of chemoradiotherapy with cisplatin + S-1 versus cisplatin + pemetrexed for locally advanced non-squamous non-small cell lung cancer: SPECTRA study.
Niho S, Yoshida T, Akimoto T, Sakamaki K, Ono A, Seto T, Nishio M, Yamamoto N, Hida T, Okamoto H, Kurata T, Satouchi M, Goto K, Yamanaka T, Ohe Y. Niho S, et al. Lung Cancer. 2020 Mar;141:64-71. doi: 10.1016/j.lungcan.2020.01.008. Epub 2020 Jan 10. Lung Cancer. 2020. PMID: 31955002 Clinical Trial.
Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy after induction therapy with carboplatin, pemetrexed, and bevacizumab in patients with advanced non-squamous non small cell lung cancer.
Karayama M, Inui N, Fujisawa T, Enomoto N, Nakamura Y, Kuroishi S, Yokomura K, Koshimizu N, Sato M, Toyoshima M, Shirai T, Masuda M, Yamada T, Imokawa S, Suda T. Karayama M, et al. Eur J Cancer. 2016 May;58:30-7. doi: 10.1016/j.ejca.2016.01.013. Epub 2016 Feb 27. Eur J Cancer. 2016. PMID: 26922170 Clinical Trial.
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C. Paz-Ares L, et al. Lancet Oncol. 2012 Mar;13(3):247-55. doi: 10.1016/S1470-2045(12)70063-3. Epub 2012 Feb 16. Lancet Oncol. 2012. PMID: 22341744 Clinical Trial.
236 results